
Sign up to save your podcasts
Or


After being diagnosed with multiple myeloma at age 31, Brice Davis faced challenges that extended far beyond treatment alone. Join us as he talks about balancing fatherhood, navigating mental health struggles, rebuilding after setbacks, and adjusting to life with a chronic blood cancer. Brice reflects on the importance of community, resilience, and focusing on what matters most while creating a fulfilling life after diagnosis.
Mentioned on this episode:
Additional Blood Cancer United Support Resources:
Episode supported by Adaptive Biotechnologies Corporation; GSK plc; and Johnson & Johnson.
The post Myeloma, Fatherhood, and Moving Forward first appeared on The Bloodline with Blood Cancer United Podcast.
You cannot have progress without research.
In our latest episode, Dr. Jay Yang of the Karmanos Cancer Institute in Detroit, MI, breaks down the essentials of MDS care, from risk-based treatment plans to managing fatigue and exploring promising new therapies. Tune in to find out why the future of MDS treatment is brighter than ever.
Mentioned on this episode:
Additional Blood Cancer United Support Resources:
Episode supported by Bristol Myers Squibb and Taiho Oncology, Inc.
The post Myelodysplastic Syndromes (MDS): Progress, Possibility, and What’s Next first appeared on The Bloodline with Blood Cancer United Podcast.
Two college students. Two lymphoma diagnoses. One unexpected love story.
In this episode, we speak with Kim and Josh Woda, who were both diagnosed with Hodgkin lymphoma while attending college. They share how they navigated school during treatment, coped with relapse and stem cell transplant, found support in the cancer community, and unexpectedly found each other. Their story is a powerful reminder that connection, understanding, and hope can appear when you least expect it.
Mentioned on this episode:
Additional Blood Cancer United Support Resources:
Episode supported by Kyowa Kirin Pharmaceutical Development Inc and Merck & Co.
The post Finding Each Other Along the Way: A Cancer Love Story first appeared on The Bloodline with Blood Cancer United Podcast.
What does a myelofibrosis (MF) diagnosis really mean, and how does it fit within a group of conditions called myeloproliferative neoplasms, or MPNs? In this episode, we’re joined by Dr. Tania Jain of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, who helps break it all down in a clear and approachable way.
She discusses how myelofibrosis affects the bone marrow, common symptoms to watch for, and how treatment options are tailored to each person. From managing day-to-day challenges to understanding when more advanced treatments may be considered, this conversation focuses on what matters most to patients and families.
As Dr. Jain shares, “every patient writes their own story,” noting that advancing research offers genuine hope.
Mentioned on this episode:
Additional Blood Cancer United Support Resources:
Episode supported by Takeda Oncology.
The post Myelofibrosis (MF): More Options, More Hope first appeared on The Bloodline with Blood Cancer United Podcast.
Acute myeloid leukemia (AML) is a complex diagnosis, and it can be difficult to know what to expect in those early conversations after diagnosis. In this episode, we speak with Dr. Rebecca Olin from the University of California, San Francisco (UCSF), who helps explain what AML is and how care is approached today.
Dr. Olin walks us through how doctors evaluate AML, what factors influence treatment decisions, and how therapies – including targeted treatments, stem cell transplant, and clinical trials – are helping improve outcomes and quality of life. We also discuss the importance of supportive care and ongoing research, offering listeners a clearer picture of how AML is treated now and where progress continues to be made.
Mentioned on this episode:
Additional Blood Cancer United Support Resources:
Episode supported by Astellas Pharma US Inc.; Daiichi Sankyo Inc.; Debiopharm; Genentech, A Member of the Roche Group; and Kura Oncology, Inc.
The post Acute Myeloid Leukemia (AML): New Approaches For A Complex Diagnosis first appeared on The Bloodline with Blood Cancer United Podcast.
With so many new advances in acute lymphoblastic leukemia (ALL), understanding today’s treatment landscape can give patients a clearer, more hopeful outlook.
In this episode, we speak with Marlise Luskin, MD of the Dana-Farber Cancer Institute, about what adults should know when facing a diagnosis of acute lymphoblastic leukemia. Dr. Luskin helps listeners understand how ALL develops, how subtypes are identified, and why genetics play an important role in guiding treatment. She discusses current therapies including chemotherapy, targeted agents and immunotherapies including CAR T-cell therapy, as well as how care teams monitor progress and manage side effects. While ALL is a complex disease, patients and caregivers will hear clear explanations, practical information, and meaningful reasons to feel hopeful about the advances shaping ALL care today.
Mentioned on this episode:
Additional Blood Cancer United Support Resources:
Episode supported by Syndax Pharmaceuticals Inc.
The post Acute Lymphoblastic Leukemia (ALL): The New Tools Shaping Tomorrow first appeared on The Bloodline with Blood Cancer United Podcast.
Multiple myeloma can feel unfamiliar and overwhelming at first, but today’s advances tell a much brighter story.
In this episode, Dr. Andrew Yee of Massachusetts General Hospital explains what myeloma is, how it’s diagnosed, and why new treatment options, from four-drug regimens to CAR T-cell therapy and bispecific antibodies, are transforming patient outcomes. With enthusiasm and relatable analogies, he highlights how patients may progress from periods of significant challenges to reaching a level of stability and well‑being that allows them to live fully. This conversation offers clarity, confidence, and real optimism for anyone navigating myeloma.
Mentioned on this episode:
Additional Blood Cancer United Support Resources:
Episode supported by AbbVie Inc.; Bristol Myers Squibb; Genentech, A Member of the Roche Group; GSK plc.; Johnson & Johnson.
The post Facing Multiple Myeloma: A Guide to Choices, Care, and Confidence first appeared on The Bloodline with Blood Cancer United Podcast.
Curious about what’s new in the world of myelodysplastic syndromes (MDS)? We’re bringing you the latest insights straight from one of the field’s leading experts.
In this episode, we speak with Dr. Mikkael Sekeres, of the Sylvester Comprehensive Cancer Center at University of Miami Health. Recorded onsite at the 2025 ASH (American Society of Hematology) Annual Meeting and Exposition, this conversation explores what MDS is, how it’s treated today, and what researchers are learning about managing side effects.
Dr. Sekeres also walks us through the most notable MDS updates presented at ASH, highlighting promising therapies and clinical trial data that may help shape future care. Whether you’re newly learning about MDS or following ongoing research, this episode offers an accessible look at where things stand and what’s on the horizon.
*This is not an official program of the ASH annual meeting
Mentioned on this episode:
Additional Blood Cancer United Support Resources:
Episode supported by Geron Corporation and Taiho Oncology, Inc.
The post The Bloodline Live! Myelodysplastic Syndromes (MDS) Updates in Research first appeared on The Bloodline with Blood Cancer United Podcast.
Non-Hodgkin lymphoma (NHL) can sound overwhelming, but what does it really mean for patients and families? In this episode, we speak to Dr. Jean Koff of Winship Cancer Institute of Emory University, who breaks down the big picture of NHL: what it is, how it’s an umbrella term for multiple subtypes, and what today’s treatments and tomorrow’s innovations could mean for you. From understanding subtypes and staging to exploring options like watchful waiting, chemotherapy, and cutting-edge immunotherapies, we cover what matters most: knowledge, clarity, and hope.
Mentioned on this episode:
Additional Blood Cancer United Support Resources:
Supported by AbbVie Inc. and Genentech, A Member of the Roche Group.
The post The Big Picture on Non-Hodgkin Lymphoma: Treatments, Trends, and Tomorrow first appeared on The Bloodline with Blood Cancer United Podcast.
In this episode, we speak with Dianne Callahan, four-time cancer survivor, best-selling author, speaker, and patient advocate. Dianne shares her experiences with non-Hodgkin lymphoma and breast cancer, stem cell transplant, and survivorship while highlighting the importance of advocacy, joy, and intention in life after diagnosis. From her work with fundraising campaigns to legislative advocacy on Capitol Hill, Dianne offers inspiring insights on resilience, hope, and the power of living intentionally.
Mentioned on this episode:
Additional LLS Support Resources:
Supported by Genentech, A Member of the Roche Group.
The post Joy, Hope, and Healing Beyond a Cancer Diagnosis first appeared on The Bloodline with Blood Cancer United Podcast.
From the publisher's feed